Robust Optimization of SBRT Planning for Patients With Early Stage Non-Small Cell Lung Cancer

Haijiao Shang, MSc1,2, Yuehu Pu, PhD1,2, and Yuenan Wang, PhD3

Abstract

Purpose: Setup uncertainty is a known challenge for stereotactic body radiotherapy planning. Using the internal target volume-based robust optimization was proposed as a more accurate way than the conventional planning target volume-based optimization when considering the robustness criteria. In this study, we aim to investigate the feasibility of internal target volume-based robust optimization in stereotactic body radiotherapy planning using 4-dimensional computed tomography and develop a novel dose–volume histogram band width metric to quantitatively evaluate robustness. Method and Materials: A total of 50 patients with early stage non-small cell lung cancer, who underwent stereotactic body radiotherapy, were retrospectively selected. Each of the 50 patients had 2 stereotactic body radiotherapy plans: one with the conventional planning target volume-based optimization and the other with patient-specific robustly optimized internal target volume and with a uniform 5 mm setup error. These were compared with the planning target volume-based optimization method based on both plan quality and robustness. The quality was evaluated using dosimetric parameters and radiobiology parameters, such as high-dose spillage ($V_{90\%RX}$, conformity index), intermediate-dose spillage (dose falloff products), low-dose spillage (normal tissue: $V_{50\%RX}$), and lung tissue complication probability. The robustness was evaluated under a uniform 3 to 5 mm setup errors with a novel proposed metric: dose–volume histogram band width. Results: When compared with planning target volume-based optimization plans, the internal target volume-based robust optimization plans have better conformity of internal target volume coverage (conformity index: 1.17 vs 1.27, $P < .001$), intermediate-dose spillage (dose falloff product: 129 vs 167, $P < .001$), low-dose spillage in normal tissue ($V_{50\%RX}$: 0.8% vs 1.5%, $P < .05$), and lower risk of radiation pneumonitis (lung tissue complication probability: 4.2% vs 5.5%, $P < .001$). For the robustness, dose–volume histogram band width analysis shows that the average values in internal target volume, $D_{95\%}$, $D_{98\%}$, and $D_{99\%}$, of internal target volume-based robust optimization are smaller than that of planning target volume-based optimization (unit cGy) under 3-, 4-, and 5-mm setup uncertainties (3-mm setup uncertainty: 42 vs 73 cGy; 4-mm setup uncertainty: 88 vs 176 cGy; 5-mm setup uncertainty: 229 vs 490 cGy), which might indicate that internal target volume-based robust optimization harbored a greater robustness regardless of the setup errors. Conclusions: Internal target volume-based robust optimization may have clinical potential in offering better plan quality in both target and organs at risk and lower risk of radiation pneumonitis. In addition, the proposed internal target volume-based robust optimization may demonstrate robustness regardless of different setup uncertainties in the stereotactic body radiotherapy planning. Registration: Retrospective study with local ethics committee approval.

Keywords

stereotactic body radiotherapy (SBRT), robust optimization (RO), dose volume histogram bands width (DVHBW), radiation pneumonitis (RP)

1 Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, People’s Republic of China
2 University of Chinese Academy of Sciences, Beijing, People’s Republic of China
3 Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People’s Republic of China

Corresponding Authors:

Yuehu Pu, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, 201800, Shanghai, People’s Republic of China.
Email: puyuehu@sinap.ac.cn

Yuenan Wang, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People’s Republic of China.
Email: yuenan.wang@gmail.com

Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Stereotactic body radiation therapy (SBRT) involves the delivery of a single high dose radiation treatment or few fractionated radiation treatments, which showed high local control in tumors. According to the International Commission Radiological Units (ICRU) report, the concept of the planning target volume (PTV) is commonly used to account for tumor motion and setup uncertainty. The internal target volume (ITV) is technically the motion envelope encompassing the clinical target volume (CTV).

However, the optimal margin for the setup uncertainty from ITV to PTV is controversial, as it can be reduced by updating the image-guided radiation therapy (IGRT) equipment. Cristina Garibaldi et al. found that setup uncertainties could be brought down to about 3 mm, in all directions, using a cone-beam computed tomography (CT). Richmond et al. recommended an ITV expansion margin of 4 mm, in all directions, to compensate for residual setup uncertainties in image-guidance and intrafraction motion for patients immobilized in a body-fx device. Therefore, a conventional SBRT plan optimized with a 5-mm uniform margin PTV on the ITV may unnecessarily increase the volume of the irradiated normal tissue (NT). An additional problem is that the PTV concept as typically applied in intensity modulated radiotherapy (IMRT) planning relies on the so-called static dose cloud approximation. The underlying assumption is that the dose distribution in the treatment room coordinates is not affected by changes in the patient’s anatomy. That is, it is assumed that the CTV receives the prescribed dose if it stays within the PTV. This fundamental assumption is not generally fulfilled and is violated.

Various efforts have been made by previous studies to reduce the PTV margin. Li et al. proposed a true 4-dimensional planning method (t4Dplan) on IMRT using 4-dimensional computed tomography (4DCT) data sets to maximize the sparing of critical structures. The rationale of the t4Dplan method is to deliver a smaller dose to the tumor when the tumor is at its T0 position and deliver higher doses when it is close to its T50 position. This will compensate for the under dosing at the T0 position, given that patients spend more time in the T50 phase than in the T0 phase during the entire respiratory cycle. Their studies indicate that the t4Dplan method does not need a target margin, which improves the sparing of normal structures. Suh et al. developed a 4-dimensional (4D)-IMRT treatment planning method by modifying and applying a dynamic multileaf collimator motion-tracking algorithm. A 4D treatment plan was created based on a 4DCT image that was flexible enough to account for changes in patient setup during the treatment. These gating and tracking strategies were effective in reducing the volume of the irradiated target; however, they resulted in markedly extended treatment times and could not be widely used in clinical practice.

Recently, a new strategy to deal with the setup uncertainty, that uses a robust optimization algorithm instead of PTV margin-based optimization, has been reported to be effective in compensating for the setup uncertainty in treatment planning. Zhang et al. evaluated CTV-based robust optimization for lung cancer, and the results demonstrated that a robust optimization can generate plans that offer increased sparing of organ at risk (OAR); especially, for normal lung tissue and OARs near the target. Liang et al. evaluated ITV-based robust optimization (RO-ITV) for lung cancer with SBRT planning and showed that it can account for setup uncertainties.

In our study, we extended the RO-ITV technique to SBRT planning by accounting for plan quality and plan robustness. Innovation is mainly carried out from the following 2 aspects: On one hand, the plan quality considers more details that are of clinical concern, such as dose falloff product (DFP) for dose sharpness and the normal tissue complication probability (NTCP) model for radiation pneumonitis (RP). On the other, we developed a new metric, which is the dose–volume histogram band width (DVHBW), as an independent parameter (or dosimetric endpoint) to quantitatively assess the robustness of the plan, and whether its robustness is affected by updating the IGRT equipment. The proposed DVHBW method provides a simple metric to compare the robustness of different SBRT plans with statistical evaluation.

Materials and Methods

Patient and Plan Data Characteristics

A total of 50 patients with early stage (IA/IB) non-small cell lung cancer (NSCLC) were treated with SBRT and...
retrospectively selected for this study, which was approved by the local institutional research review board. Gross target volumes (GTVs) were contoured by the attending radiation oncologists, on each phase of the 4DCT, and ITVs were created by encompassing the extent of 10 GTV motion in all 10 phases of 4DCT. The ITV was expanded with the setup uncertainty from the PTV by including a setup uncertainty of 5 mm in the superior–inferior, anterior–posterior (AP), and left–right (LR) directions. The median ITV volume was 19.94 cm$^3$ (range of 0.92-70.82 cm$^3$) and the median PTV volume was 47.56 cm$^3$ (range of 5.87-133.20 cm$^3$).

All clinical SBRT plans used the VMAT (RapidArc) technique with the Edge linear accelerator (Linac; Varian Medical Systems, Palo Alto, California) and a 120-leaf multileaf collimation (MLC) flattening filter free mode (6 MV and 1200 MU/min dose rate). The treatment plans were created in the Eclipse TPS version11 (Varian Medical Systems) with the prescription dose of 50 Gy in 4 fractions. A summary of the patients’ information is listed in Table 1. The dose prescription was 50 Gy in 4 fractions, that is, 12.5 Gy per fraction.

**Treatment Planning**

All patients data (Image sets, RtStructure) are imported into the RayStation (Ver.8B, Raysearch Labs, Sweden), and 2 types of SBRT plans, using PTV-based conventional optimization (CO-PTV) and RO-ITV, are regenerated using the same beam geometry as clinical SBRT plans in Raystation. However, the prescribed dose of all plans is directly delivered to the ITV, with each plan normalized such that 100% of the prescribed dose covered 95% of the ITV. Moreover, patient setup uncertainty is differently handled; while the RO-ITV plan using a robust optimization algorithm is based on ITV. As described by Fredriksson et al.\textsuperscript{12-14}, the robust optimization in RayStation is a minimax optimization. The minimax optimization method minimizes the objective function value such that the prescription dose is valid even in the worst-case scenario and with respect to setup uncertainties. In practice, over 95% of the ITV volume received prescription dose ($D_{95\%}$ $\geq$ 5000 cGy) and 99% of the ITV volume received 90% of prescription dose ($D_{99\%} \geq$ 4500 cGy) are used in the robust function, in which patient setup uncertainties are taken into account by shifting the plan isocenter 5 mm in the LR direction, 5 mm in the inferior-superior direction, and 5 mm in the AP direction. Thus, the worst-case robust optimization took into account 6 setup uncertainties and generated SBRT plans by minimizing the penalty of the worst cases for the ITV. Another important point is that, in order to minimize dose spillage, auxiliary structures, such as 2 rings compassing the target area, should have lower dose limits compared with CO-PTV. This is due to the volume of the ITV, which is smaller than that of the PTV, and which results in steep gradient falloffs, away from the target edge.

The interfraction motion is generally more complex to model and is often modeled as a setup error.\textsuperscript{15} A treatment plan, which only considers fixed setup errors, yields a dose distribution which is comparable to a CO-PTV. Actually, setup errors might be averaged over the course of treatment and most studies in the IMRT model the setup errors using Gaussian distributions in 3 dimensions. The integration of uncertainties, with setup errors into the optimization process, induces an automatic expansion of CTV that expect a dose, which covers enough target under uncertainties. Sir et al.\textsuperscript{16} investigated in detail the setup errors of what the shape of the dose falloff, at the edge of the target volume, depends on.

**Plan Quality Evaluation**

Both RO-ITV and CO-PTV plans were normalized to have 5000 cGy at ITV of $D_{95\%}$. The dosimetric parameters, including ITV dose coverage, conformity index (CI), homogeneity index (HI), DFP, and OARs are compared for RO-ITV and CO-PTV according to ICRU 0915.

The ITV dose coverage is described as $99\%$ of the target volume (ITV) that received a minimum of $90\%$ of the prescription dose (ITV: $F_{90\%RX} \geq 99\%$).

The CI is calculated using Equation 1:

$$CI = \frac{V_{R\%I}}{V_{TV}}$$

(1)

Where $V_{R\%I}$ is the prescription isodose volume and $TV$ the ITV volume.

The HI is calculated using Equation 2:

$$HI = \frac{D_{2\%} - D_{98\%}}{D_{50\%}}$$

(2)

Where $D_{2\%}$, $D_{98\%}$, and $D_{50\%}$ are the doses that cover $2\%$, $98\%$, and $50\%$ of the ITV, respectively. The DFP, defined as the product of $R_{50\%}$ and $D_{2cm}$, was found to have a weak relationship with tumor size and is therefore used to compare the intermediate-dose spillage of the SBRT plan.\textsuperscript{17} DFP is expressed by Equation 3:

$$DFP = R_{50\%} \times D_{2cm}$$

(3)

Where $R_{50\%}$ is the ratio of $50\%$ of the prescription isodose volume to the ITV and $D_{2cm}$ is the maximum dose at 2 cm from the ITV in any direction.

The OARs are also evaluated using dose–volume histogram (DVH) metrics, such as lung ($D_{mean}$, $V_{20}$), spinal cord $D_{1cc}$ and NT ($V_{50\%RX}$), where NT is a ring with body minus boundary that is away from ITV is 2 cm; $V_{50\%RX}$ is NT volume received a minimum prescription dose of 50%.

**Toxicity Assessment**

The dose–volume relationships for lung complications has been studied for several years in lung cancer. The popular Lman normal tissue complication (NTCP) model was used to fit the dose–volume relationship to the clinical data. However, there are large uncertainties in the NTCP model and its associated model parameters, which might reflect...
subjectivity in the scoring complications, disparity in end points, and dosimetric uncertainties. In current studies, the Lyman NTCP model in the Moiseenko studies\(^{18}\) is used to assess the dependence of lung complications incidence on the dose–volume for both RO-ITV and CO-PTV plans. The parameters details are presented in Table. 2. In the Moiseenko studies, long survival allowed the assessment of lung complications data in patients with thymoma for acute and late response, which make the model parameters best suited for their data.

| Patient No. | Tumor Stage | ITV, cm\(^3\) | PTV, cm\(^3\) | Prescription Dose, Gy |
|-------------|-------------|---------------|---------------|------------------------|
| 1           | IA          | 23.44         | 47.05         | 12.5 Gy × 4fx          |
| 2           | IA          | 7.77          | 24.83         | 12.5 Gy × 4fx          |
| 3           | IB          | 34.63         | 94.12         | 12.5 Gy × 4fx          |
| 4           | IA          | 4.18          | 17.79         | 12.5 Gy × 4fx          |
| 5           | IA          | 4.26          | 15.14         | 12.5 Gy × 4fx          |
| 6           | IB          | 27.11         | 84.12         | 12.5 Gy × 4fx          |
| 7           | IB          | 37.35         | 85.54         | 12.5 Gy × 4fx          |
| 8           | IA          | 4.81          | 19.16         | 12.5 Gy × 4fx          |
| 9           | IA          | 7.71          | 24.76         | 12.5 Gy × 4fx          |
| 10          | IB          | 27.36         | 48.06         | 12.5 Gy × 4fx          |
| 11          | IB          | 47.55         | 91.28         | 12.5 Gy × 4fx          |
| 12          | IA          | 0.92          | 5.87          | 12.5 Gy × 4fx          |
| 13          | IB          | 13.97         | 38.01         | 12.5 Gy × 4fx          |
| 14          | IB          | 70.82         | 133.2         | 12.5 Gy × 4fx          |
| 15          | IB          | 36.49         | 82.26         | 12.5 Gy × 4fx          |
| 16          | IB          | 35.43         | 71.59         | 12.5 Gy × 4fx          |
| 17          | IB          | 29.23         | 51.25         | 12.5 Gy × 4fx          |
| 18          | IB          | 33.33         | 87.26         | 12.5 Gy × 4fx          |
| 19          | IA          | 9.52          | 28.62         | 12.5 Gy × 4fx          |
| 20          | IB          | 26.66         | 63.35         | 12.5 Gy × 4fx          |
| 21          | IA          | 19.73         | 48.06         | 12.5 Gy × 4fx          |
| 22          | IB          | 47.98         | 90.31         | 12.5 Gy × 4fx          |
| 23          | IA          | 9.04          | 29.96         | 12.5 Gy × 4fx          |
| 24          | IA          | 3.69          | 11.33         | 12.5 Gy × 4fx          |
| 25          | IB          | 30.24         | 52.15         | 12.5 Gy × 4fx          |
| 26          | IA          | 2.95          | 13.27         | 12.5 Gy × 4fx          |
| 27          | IB          | 64.45         | 125.02        | 12.5 Gy × 4fx          |
| 28          | IA          | 8.24          | 24.78         | 12.5 Gy × 4fx          |
| 29          | IA          | 6.89          | 22.65         | 12.5 Gy × 4fx          |
| 30          | IA          | 17.22         | 40.32         | 12.5 Gy × 4fx          |
| 31          | IA          | 20.15         | 53.47         | 12.5 Gy × 4fx          |
| 32          | IB          | 56.43         | 98.56         | 12.5 Gy × 4fx          |
| 33          | IA          | 8.67          | 27.69         | 12.5 Gy × 4fx          |
| 34          | IB          | 52.65         | 93.57         | 12.5 Gy × 4fx          |
| 35          | IA          | 5.88          | 22.65         | 12.5 Gy × 4fx          |
| 36          | IB          | 62.86         | 119.68        | 12.5 Gy × 4fx          |
| 37          | IA          | 3.56          | 10.74         | 12.5 Gy × 4fx          |
| 38          | IA          | 12.62         | 36.66         | 12.5 Gy × 4fx          |
| 39          | IB          | 36.88         | 80.98         | 12.5 Gy × 4fx          |
| 40          | IB          | 66.86         | 124.68        | 12.5 Gy × 4fx          |
| 41          | IB          | 49.89         | 96.68         | 12.5 Gy × 4fx          |
| 42          | IA          | 4.89          | 20.38         | 12.5 Gy × 4fx          |
| 43          | IB          | 32.62         | 60.88         | 12.5 Gy × 4fx          |
| 44          | IA          | 3.88          | 12.28         | 12.5 Gy × 4fx          |
| 45          | IB          | 46.66         | 88.62         | 12.5 Gy × 4fx          |
| 46          | IA          | 6.84          | 20.66         | 12.5 Gy × 4fx          |
| 47          | IA          | 5.68          | 21.28         | 12.5 Gy × 4fx          |
| 48          | IA          | 16.56         | 42.66         | 12.5 Gy × 4fx          |
| 49          | IA          | 12.42         | 32.86         | 12.5 Gy × 4fx          |
| 50          | IB          | 58.88         | 102.68        | 12.5 Gy × 4fx          |

Median (range) 19.94 (0.92-70.82) 47.56 (5.87-133.20)

Abbreviations: ITV, internal target volume; NSCLC, non-small cell lung cancer; PTV, planning target volume.
ITV target (metric, in the ITV coverage, to the setup uncertainty in the values of variation of DVH metrics in a setup group. In our studies, the included the DVHBW. computed for each setup group. In the case of the ITV, the metrics follows:

\[ \text{DVHBW} = \frac{\text{max}(D^s)}{\text{mean}(D^s)} \]

where \( D^s \) is the DVH metric of the ITV in relative volume (%) for setup group \( s \). In short, the DVHBW represents the variation of DVH metrics in a setup group. In our studies, the values of \( s \) are 95, 98, and 99, due to the sensitivity of the DVH metric, in the ITV coverage, to the setup uncertainty in the SBRT planning. A total of 3 DVHBWs were obtained in the ITV target (\( D_{50}, D_{95}, D_{99} \)) under 1 setup group, in which it was separately compared between the RO-ITV and CO-PTV plans. Furthermore, the mean DVHBW was calculated by averaging 3 DVHBWs for 1 group.

Another metric, the voxel-wise dose distribution (VWDD), was introduced for plan robustness. The VWDD-min as an aggregate dose distribution based on the minimum dose value, in each voxel over all scenarios, was used to evaluate the target coverage. The VWDD-max, which is an aggregate dose distribution based on the maximum dose value, in each voxel over all scenarios, was used to evaluate OAR sparing.

### Robustness Quantification

Although a patient setup uncertainty of 5 mm was introduced for both CO-PTV and RO-ITV in SBRT planning, it was necessary to study the situation in which the setup uncertainty is less than 5 mm in the evaluation of robustness, which could be caused by updating the IGRT equipment. Therefore, the evaluation of robustness in SBRT planning started with the creation of 3 scenarios or setup groups whose details are as follows:

1. **3-mm setup group**: nominal scenario (no setup uncertainty) and 14 uncertainty scenarios (6 with 3 mm in X, Y, and Z directions, respectively; and 8 with 3 mm in diagonal directions) that simulate a 3-mm maximum setup isotropic space.
2. **4-mm setup group**: nominal scenario (no setup uncertainty) and 14 uncertainty scenarios (6 with 4 mm in X, Y, and Z directions, respectively; and 8 with 4 mm in diagonal directions) that simulate a 4-mm maximum setup isotropic space.
3. **5-mm setup group**: nominal scenario (no setup uncertainty) and 14 uncertainty scenarios (6 with 5 mm in X, Y, and Z directions, respectively; and 8 with 5 in diagonal directions) that simulate a 5-mm maximum setup isotropic space.

Hence, a total of 15 perturbed dose distributions were computed for each setup group. In the case of the ITV, the metrics included the DVHBW. The DVHBW can be expressed by Equation 4:

\[ \Delta D_e = \max(D_e^s) - \min(D_e^s) \]

where \( D_e^s \) is the DVH metric of the ITV in relative volume (%) for setup group \( s \). In short, the DVHBW represents the variation of DVH metrics in a setup group. In our studies, the values of \( s \) are 95, 98, and 99, due to the sensitivity of the DVH metric, in the ITV coverage, to the setup uncertainty in the SBRT planning. A total of 3 DVHBWs were obtained in the ITV target (\( D_{50}, D_{95}, D_{99} \)) under 1 setup group, in which it was separately compared between the RO-ITV and CO-PTV plans. Furthermore, the mean DVHBW was calculated by averaging 3 DVHBWs for 1 group.

Another metric, the voxel-wise dose distribution (VWDD), was introduced for plan robustness. The VWDD-min as an aggregate dose distribution based on the minimum dose value, in each voxel and over all scenarios, was used to evaluate the target coverage. The VWDD-max, which is an aggregate dose distribution based on the maximum dose value, in each voxel over all scenarios, was used to evaluate OAR sparing.

### Statistical Analysis

The student t test was carried out to compare the pairwise difference between 2 treatment techniques (CO-PTV and RO-ITV) in term of plan quality, risk of RP, and plan robustness. A \( P \) value < .05 was considered statistically significant. A study was performed using a nonlinear model with Excel software version (v.2016, Microsoft; https://www.microsoft.com) to evaluate the correlation between the mean DVHBW and 3 setup groups.

### Results

#### Target Dose Coverage

In general, RO-ITV met the ITV coverage and critical organ dose objectives according the Radiation Therapy Oncology Group (RTOG) 0915 were used for the SBRT plans. In Figure 1, more details are shown, comparing RO-ITV to CO-PTV.

The most important target coverage parameters, \( V_{90\%RX} \) and \( V_{100\%RX} \), are satisfied by both RO-ITV and CO-PTV plans, without no significant differences between them.

1. An acceptable CI was defined as <1.2 and <1.5 for a deviation in RTOG 0915. The value of CI for RO-ITV was 1.17 for RO-ITV versus 1.27 for CO-PTV (\( P < .01 \); for ITV).
2. Although a HI was not required by RTOG 0915, we observed that the HI was 0.18 for RO-ITV versus 0.17 for CO-PTV (\( P < .05 \)).
3. The falloff gradient beyond the ITV that extends into NT structures should be steep in all directions and meet \( R_{50\%} \) and \( D_{2cm} \) according to RTOG 0915. The DFP, as an effective metric and regardless of tumor size, was investigated and found to be better in RO-ITV. For ITV, it was 129 for RO-ITV versus 167 for CO-PTV (\( P < .001 \)).

#### Organ at Risk and RP

Many dosimetric OAR parameters were lower for RO-ITV compared to CO-PTV (Figure 2). The mean dose in lung tissue (\( D_{mean} \)) was 415 cGy for RO-ITV compared to 451 cGy for CO-PTV (\( P < .05 \)) and the lung \( V_{20\%} \) values were 5.4% for RO-ITV compared to 6.0% for CO-PTV (\( P < .05 \)). In addition, the 50% prescription isodose volume (\( V_{50\%RX} \)) in the NT was significantly lower when irradiated with the RO-ITV plans (\( P < .05 \)).

The SBRT plan with the RO-ITV methods revealed significantly superior mean NTCP values for the lung (NTCP = 4.2%) compared to CO-PTV (NTCP = 5.5%; \( P < .05 \); Figure 3). Consequently, the RO-ITV demonstrated a lower risk of RP compared to the CO-PTV technique for the lung.

### Table 2. Parameters Used in the Lyman-Kutcher-Burman Model.

| Parameter | Volume | \( D_{50} \), cGy | M | N | \( \alpha/\beta \), Gy |
|-----------|--------|----------------|---|---|---------------------|
| NTCP      | Both lungs | 2190 | 0.37 | 0.8 | 3 |

Abbreviation: NTCP, normal tissue complication probability.
Robustness Analysis: DVHB

A 5-mm setup uncertainty may be an overestimate due to the updating of immobilization and image-guided devices during patient treatment delivery. Therefore, the effects of 3- and 4-mm setup uncertainties on the plan are also evaluated. Figure 4A-C shows a comparison of the ITV-DVHBW using the DVH metric ($D_{95}$, $D_{98}$, $D_{99}$) under 3-, 4-, and 5- setup groups between the RO-ITV and CO-PTV plans and with average values for all directions. Further details include:

1. For the 3-mm setup group, it was observed that the mean DVHBW is smaller in RO-ITV: for ITV ($D_{99}$), it was 48 cGy for RO-ITV versus 80 cGy for CO-PTV ($P < .01$); for ITV ($D_{98}$), it was 42 cGy for RO-ITV versus 78 cGy for CO-PTV ($P < .01$); and for ITV ($D_{95}$), it was 38 cGy for RO-ITV versus 62 cGy for CO-PTV ($P < .01$). On the other hand, the mean DVHBs were reduced from ITV ($D_{99}$) to ITV ($D_{95}$), due to the sensitivity of $D_{99}$ to the setup uncertainty compared to $D_{95}$.

2. A narrow DVHBW for RO-ITV and a lower DVHB value for $D_{95}$ were also observed for the 4-mm setup and 5-mm setup groups (see Figure 4B and C for specific average values). We also found that the average DVHBW in $D_{95}$, $D_{98}$, and $D_{99}$ increased from the 3-mm setup to the 5-mm setup group (Figure 4D). The average DVHBW was 42 cGy for the RO-ITV plans compared to 73 cGy for the CO-PTV plans in the 3-mm setup group; 88 cGy for the RO-ITV plans compared to 176 cGy for the CO-PTV plans in the 4-mm setup group; 229 cGy for the RO-ITV plans to 490 cGy for the CO-PTV plans in the 5-mm setup group.

3. A statistical correlation study was performed to evaluate the correlation between the average DVHBW and the setup group and showed the existence of an exponential relationship between the 2 (Figure 4D). For RO-ITV, the expression was $\Delta D_{RO-ITV} = 2.8e^{1.03r}$; while for the CO-PTV plans, it was $\Delta D_{CO-PTV} = 1.6e^{0.9r}$, where $r$ is equal to 3, 4, and 5 mm. It was observed that the DVHBW in CO-PTV plans was much steeper than in RO-ITV plans, which indicated that while SBRT planning against setup uncertainties can be improved by robust optimization methods, this improvement decreases exponentially with increased setup uncertainty.

**Figure 1.** Plan quality comparison between RO-ITV and CO-PTV in $V_{90}$, HI, CI, and DFP. CI indicates conformity index; CO-PTV, planning target volume-based conventional optimization; DFP, dose falloff product; HI, homogeneity index; RO-ITV, internal target volume-based robust optimization.
The VWDD-min/max are used in the transverse plane for a representative patient to illustrate the robustness of RO-ITV plans (Figure 5, right panels) against setup uncertainty when compared with CO-PTV plans (Figure 5, left panels). The 5000 and 4500 dose line covered a greater ITV volume in the RO-ITV plans, as determined by the VWDD-min (Figure 5A and D). It was also observed that less volume was irradiated in the RO-ITV plans using the 2500 cGy dose line on the VWDD-max (Figure 5B and E) for NT organ. In addition, RO-ITV plans provided better target coverage according to the ITV-DVH metric ($V_{100\%RX}$) than the CO-PTV plans in the worst-case scenario (92.1% vs 82.3%) and are shown in Figure 5C and F.

**Discussion**

The purpose of this study is to investigate the feasibility of SBRT planning using RO-ITV methods. To this end, we performed a comprehensive comparison between the RO-ITV and CO-PTV optimization methods based on plan quality and robustness for patients with early stage NSCLC. The goal of lungs SBRT is to deliver an ablative dose to a lung tumor while sparing as much of the surrounding NT as possible. According to the RTOG protocol, the falloff gradient beyond the target structure must be steep in all directions. In the present study, the RO-ITV demonstrated its great potential in maintaining target coverage, while reducing that of NT. The conformality of tumor coverage and intermediate-dose spillage...
was evidently lower in the RO-ITV plans, as shown in Figure 1. Furthermore, we found that the RO-ITV method performed well in regions where the dose should have been minimal, such as the NT in Figure 2.

Studies have shown that when the biological effective dose is above 100 Gy, the local control and survival significantly improve for patients with early stage NSCLC. However, RP is a major form of toxicity that limits the increases in the fraction dose in SBRT for lung cancer. Numerous studies have reported that up to 29% SBRT-induced RP cases require clinical intervention. Therefore, such high standards for SBRT have led to much tighter tolerances when treatment planning was performed, and much effort was expended to limit toxicity. Our results show that SBRT plans, using RO-ITV, achieve significant sparing of lung dose compared with the CO-PTV plans, as illustrated by the lung ($D_{\text{mean}}, V_{20}$) in Figure 2. The probability of RP was also proved to be lower for RO-ITV (Figure 3). A qualitative explanation of the results goes as follows: typically, the priority in treatment planning is to make sure that the ITV receives the prescribed dose despite uncertainty. In specific cases, especially when the OARs are very close to target and NTs, it is also important for target coverage. Stereotactic body radiotherapy for lung tumors is an example, where sparing of lung NT is relative important to target coverage. In this case, the ITV is expanded by a margin, with a probability distribution that considers setup uncertainty, which might be superior than the plan where ITV is expanded by a fixed margin. Therefore, ITV robust treatment planning creates a plan that easily meets the average dose to the lung.

For the treatment centers which update image-guided devices during treatment delivery, handling the 5-mm setup uncertainty according to the ICRU protocol may result in dose overestimates. It is therefore necessary to consider plan robustness under 3- and 4-mm setup uncertainties. In our studies, 3 groups of setup uncertainties were created to investigate plan robustness, while the proposed DVHBW method was used to provide a simple metric to cross-compare the robustness of SBRT plans based on the RO-ITV and CO-PTV methods. We selected the $D_{99}$, $D_{98}$, and $D_{95}$ ITV as indicators due to their sensitivity to the setup uncertainties. The ITV ($D_{99}$) is more sensitive than the ITV ($D_{95}$) due to the need of more voxels to account for setup uncertainties, while ITV ($D_{98}$)
served as a reference value. Three values of ITV target coverage would be able to reflect the robustness of the plan under setup uncertainties. From the result shown in Figure 4A-C, the ITV-based optimization made the plan more robust against setup uncertainties. This can be explained by the algorithm used in robust optimization, which allows the planner to consider setup uncertainties before performing plan optimization. The robust optimization algorithm discretize setup uncertainties into multiple scenarios. The uncertainty in each scenario is taken into account by the objective function during plan optimization, such that the prescription holds true for each of the various setup uncertainties. An approximative exponential relationship exists between the mean DVHBW and the setup uncertainties, as illustrated in Figure 4D. This relationship indicates that, no matter which optimization method is used, the target coverage will sharply deteriorate with an increased setup uncertainty but the deterioration is slower using RO-ITV plans.

In order to simplify the method of comparing plan robustness of the RO-ITV and CO-PTV plans, DVHBW is used in the target coverage. The approach is different from a root mean square dose (RMSD)-volume histograms (RVH) method, which calculates the RMSD of the 15 doses (ie, 3-mm setup group: nominal scenario [no setup uncertainty] and 14 uncertainty scenarios [6 with 3 mm in X, Y, and Z directions, respectively; and 8 with 3 mm in diagonal directions]) for each voxel within a given structure. The area under the RVH curve in a structure gave a numerical index summarizing plan robustness similar to the way in which the equivalent uniform dose is summarized by a DVH. Thus, plan robustness could also be evaluated by comparing the area under the RVH for the ITVs of the RO-ITV and CO-PTV plans. However, RVH is an approach that actually takes into account all the voxels within the ITVs; whereas, certain voxels within ITV, for example, prescription isodose surface coverage, are more important in SBRT planning. Voxel wise min/max distribution, as a supplementary method to the DVHB metric, takes into account all the voxels within the patient’s body, from which perturbations in the dose caused by setup uncertainties are distributed at the boundary of the target area (Figure 5).

Our results provide compelling evidence for the RO-ITV plans, in which plan quality and robustness are obviously advantageous compared to the CO-PTV methods; however, some limitations are worth noting. We assumed that the CO-PTV plan was optimized to PTV coverage of the prescribed dose and then normalized to ITV 95% coverage. This may cause a down normalization of the final CO-PTV with the cost function not being the best design for it. For robust optimized plans, with normalized to 95% coverage of ITV, the cost function may a better fit. Therefore, the compromise method is to normalize the plan to ITV 99% coverage.

![Figure 5](image-url). Dose distributions in the transverse plane for a representative patient illustrate the insensitivity of RO-ITV plan (left panels) to set up uncertainties compared with the CO-PTV plan (right panels). The 5000 and 4500 cGy dose line covered a little more ITV volume in RO-ITV plans from Voxel-wise minimum dose distribution (A and D). It was observed that less volume was irradiated in RO-ITV plans according to 2500 and 2000 cGy on Voxel-wise maximum dose distribution (B and E) for NT organ. In addition, RO-ITV plans provided better target coverage in ITVs-DVH metric ($F_{100(RX)}$) than the CO-PTV plans in the worst scenario, as shown in C and F. CO-PTV indicates planning target volume-based conventional optimization; ITV, internal target volume; NT, normal tissue; RO-ITV, internal target volume-based robust optimization.
normalization that makes RO-ITV plan up and CO-PTV plan slightly down, we picked up 2 extreme cases from the patient’s cohort to verify the conclusion. Figure 6 shows the results in both plan quality (patient no. 12) and robustness (patient no. 14) with the dosimetric details shown in Table 3. Our results show that the conclusion is still valid when normalizing the plan to ITV 99% coverage for the CO-PTV and RO-ITV plans.

Another limit is associated with the intrafractional motion issue in treatment of NSCLC-SBRT, which may cause considerable changes in the relative position of the tumor geometry and the MLC aperture, which subsequently has an impact on the dose distribution of the target and the risk to surrounding organs. This is the interplay effect, which had been reported to degrade the quality of the dose delivery.\(^4\,\,25\) Notably, we did not attempt to consider issues associated with intrafractional motion, although this might be desirable since a similar issue is present in the GTV-to-ITV margin for the ITV-based plan. One group has proposed the use of the difference between the 4D accumulated dose (4DD) and the 4D dynamic accumulated dose (4DDD) to evaluate interplay effects on the treatment plan.\(^26\,\,27\) The 4DD is a static dose that averages the sum of the doses calculated during the 10 individual phases of a 4DCT image without considering time dependence in the treatment delivery. The 4DDD is a dynamic dose that considers time dependence in the treatment delivery, together with changes in anatomy, owing to respiratory motion. Studies have shown that the 4DDD converges to the 4DD, indicating that its random nature allows the effect of interplay to be averaged out after multiple fractions.\(^28\) Many studies\(^29\,\,30\) have also shown that the interplay effect does not significantly affect the cumulative dose distribution over multiple fractions. Besides interplay effects, the erratic motion of target on the treatment day that is not captured on the CT simulation is also not considered here, for example, when a patient coughs or breathes deeply on the linac but not on the CT simulation, the error could be larger in RO-ITV based approach.

5. Conclusions
Robust optimization plans provided a better quality plan for target coverage and OAR and for a lower RP according to the lung Lyman-Kutcher-Burman NTCP model. The plan robustness is also shown to be better under different kinds of setup uncertainty scenarios. A novel strategy is introduced to quantitatively evaluate robustness plan using the DVHBW. Our

**Figure 6.** Plan quality comparison (patient no. 12) and plan robustness comparison (patient no. 14) with normalization the plan to 99% coverage of ITV. ITV indicates internal target volume.

**Table 3.** Plan Quality and Robustness Comparison for 2 Representative Patients.

|                      | Patient No. 12 | Patient No. 14 |
|----------------------|----------------|----------------|
|                      | RO-ITV         | CO-PTV         | RO-ITV         | CO-PTV         |
| CI                   | 1.08           | 1.12           | 1.34           | 1.47           |
| HI                   | 0.18           | 0.17           | 0.31           | 0.26           |
| DFP                  | 143            | 157            | 288            | 369            |
| Lung \((D_{\text{mean}}, \text{cGy})\) | 325            | 340            | 684            | 787            |
| Lung \((V_{20{\%}}, \%)\) | 2.17           | 2.26           | 8.73           | 9.65           |
| Spinal cord \((D_{\text{1cc}}, \text{cGy})\) | 203            | 398            | 560            | 628            |
| NT                   | 0.3            | 0.4            | 1.46           | 1.98           |
| NTCP, %              | 3.1            | 3.2            | 4.83           | 5.46           |
| DVHBW, cGy           | 192            | 302            | 166            | 329            |

Abbreviations: CI, conformity index; CO-PTV, planning target volume-based conventional optimization; DFP, dose falloff product; DVHBW, dose–volume histogram band width; HI, homogeneity index; NT, normal tissue; NTCP, normal tissue complication probability.
studies show that DVHBW in RO-ITV is significantly lower, which makes the SBRT plan more robust against setup uncertainties. Furthermore, while target coverage sharply deteriorates (approximately exponentially) with increased setup uncertainty, the coverage with RO-ITV is likely to be better than that with CO-ITV.

**Availability of Data and Materials**
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declaration of Conflicting Interests**
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**
The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**
Haijiao Shang https://orcid.org/0000-0003-3977-1737

**References**

1. Haffty BG, Goldberg NB, Gerstley J, Fischer DB, Peschel RE. Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 1988;15(1):69-73.

2. Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LR. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the duke experience. *Int J Radiat Oncol Biol Phys*. 1998;40(1):149-154.

3. Stroom JC, Heijmen BJ. Geometrical uncertainties, radiotherapy planning margins, and the ICRU-62 report. *Radiother Oncol*. 2002;64(1):75-83.

4. Slotman BJ, Lagervwaard FJ, Senan S. 4D imaging for target definition in stereotactic radiotherapy for lung cancer. *Acta Oncol*. 2006;45(7):966-972.

5. Garibaldi C, Piperno G, Ferrari A, et al. Translational and rotational localization uncertainties in cone-beam CT based image-guided lung stereotactic radiotherapy. *Phys Med*. 2016;32(7):859-865.

6. Richmond ND, Pilling KE, Peedell C, Shakespear D, Walker CP. Positioning accuracy for lung stereotactic body radiotherapy patients determined by on treatment cone-beam CT imaging. *Br J Radiol*. 2012;85(1014):819-823.

7. Li X, Wang X, Li Y, Zhang X. A 4D IMRT planning method using deformable image registration to improve normal tissue sparing with contemporary delivery techniques. *Radiat Oncol*. 2011;6(1):83.

8. Suh Y, Sawant A, Venkat R, Keall PJ. Four-dimensional IMRT treatment planning using a DMLC motion-tracking algorithm. *Phys Med Biol*. 2009;54(12):3821-3835.

9. Zhang X, Rong Y, Morrill S, et al. Robust optimization in lung treatment plans accounting for geometric uncertainty. *J Appl Clin Med Phys*. 2018;19(3):19-26.

10. Liang X, Zheng D, Mamalui MH, et al. ITV-based robust optimization for VMAT planning of stereotactic body radiation therapy of lung cancer. *Pract Radiat Oncol*. 2019;9(1):38-48.

11. Videtic GM, Hu C, Singh AK, et al. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage i peripheral non-small cell lung cancer: NRG oncology RTOG 0915 (NCCTG N0927). *Int J Radiat Oncol Biol Phys*. 2015;93(4):757-764.

12. Fredriksson A, Forsgren A, Hardemark B. Minimax optimization for handling range and setup uncertainties in proton therapy. *Med Phys*. 2011;38(3):1672-1684.

13. Fredriksson A, Forsgren A, Hardemark B. Maximizing the probability of satisfying the clinical goals in radiation therapy treatment planning under setup uncertainty. *Med Phys*. 2015;42(7):3992-3999.

14. Fredriksson A, Bokrantz R. The scenario-based generalization of radiation therapy margins. *Phys Med Biol*. 2016;61(5):2067-2082.

15. Unkelbach J, Alber M, Bangert M, et al. Robust radiotherapy planning. *Phys Med Biol*. 2018;63(22):22TR02.

16. Sir MY, Pollock SM, Epelmen MA, Lam KLR, Ten Haken RK. Ideal spatial radiotherapy dose distributions subject to positional uncertainties. *Phys Med Biol*. 2006;51(24):6329-6347.

17. Narayanasamy G, Desai D, Morrill S, et al. Technical note: a planning technique to lower normal tissue toxicity in lung SBRT plans based on two likely dependent RTOG metrics. *Med Phys*. 2018;45(5):2325-2328.

18. Moiseenko V, Craig T, Bezjak A, Van Dyk J. Dose-volume analysis of lung complications in the radiation treatment of malignant thymoma: a retrospective review. *Radiother Oncol*. 2003;67(3):265-274.

19. Fredriksson A, Bokrantz R. A critical evaluation of worst-case optimization methods for robust intensity-modulated proton therapy planning. *Med Phys*. 2014;41(8):081708.

20. Jensen CA, Roa AMA, Johansen M, Lund JA, Frengen J. Robustness of VMAT and 3DCRT plans toward setup uncertainties in radiotherapy of locally advanced left-sided breast cancer with DIBH. *Phys Med*. 2018;45:12-18.

21. Yamashita H, Nakagawa K, Nakamura N, et al. Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. *Radiat Oncol*. 2007;2:21.

22. Liu W, Frank SJ, Li X, et al. Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers. *Med Phys*. 2013;40(5):051711.

23. Albertini F, Hug EB, Lomax AJ. Is it necessary to plan with safety margins for actively scanned proton therapy? *Phys Med Biol*. 2011;56(14):4399-4413.

24. Rao M, Wu J, Cao D, et al. Dosimetric impact of breathing motion in lung stereotactic body radiotherapy treatment using intensity modulated radiotherapy and volumetric modulated arc therapy. *Int J Radiat Oncol Biol Phys*. 2012;83(2):e251-e256.

25. Ong CL, Dahele M, Slotman BJ, Verbakel WF. Dosimetric impact of the interplay effect during stereotactic lung radiation therapy
delivery using flattening filter-free beams and volumetric modulated arc therapy. *Int J Radiat Oncol Biol Phys*. 2013;86(4):743-748.

26. Kardar L, Li Y, Li X, et al. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. *Pract Radiat Oncol*. 2014;4(6):e259-268.

27. Yu J, Zhang X, Liao L, et al. Motion-robust intensity-modulated proton therapy for distal esophageal cancer. *Med Phys*. 2016;43(3):1111-1118.

28. Li H, Li Y, Zhang X, et al. Dynamically accumulated dose and 4D accumulated dose for moving tumors. *Med Phys*. 2012;39(12):7359-7367.

29. Bortfeld T, Jiang SB, Rietzel E. Effects of motion on the total dose distribution. *Semin Radiat Oncol*. 2004;14(1):41-51.

30. Jiang SB, Pope C, Al Jarrah KM, Kung JH, Bortfeld T, Chen GT. An experimental investigation on intra-fractional organ motion effects in lung IMRT treatments. *Phys Med Biol*. 2003;48(12):1773-1784.